Bioresorbable drug-eluting magnesium-alloy scaffold: Design and feasibility in a porcine coronary model

EuroIntervention

Volumn 8, Issue 12, 2013, Pages 1441-1450

  Wittchow, Eric ^a   Adden, Nina ^a   Riedmüller, Johannes ^a   Savard, Claudine ^b   Waksman, Ron ^c   Braune, Marlen ^a  

^a Biotronik SE and Co KG ^*  (Germany)

^b SOLVO BIOTECHNOLOGY   (Hungary)

^c WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

Bioresorbable PLGA polymer; Bioresorbable scaffold; Drug eluting stent; Magnesium scaffold degradation products; Paclitaxel; Porcine coronary model

Indexed keywords

ACETYLSALICYLIC ACID; ALLOY; CLOPIDOGREL; HEPARIN; MAGNESIUM ALLOY; PACLITAXEL; POLYGLACTIN; POLYMER; UNCLASSIFIED DRUG;

ANGIOCARDIOGRAPHY; ANIMAL EXPERIMENT; ARTERIAL WALL THICKNESS; ARTICLE; CLINICAL EFFECTIVENESS; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; DRUG ELUTING STENT; ELUTION; EQUIPMENT DESIGN; FEASIBILITY STUDY; FEMALE; HISTOPATHOLOGY; MALE; MATERIAL COATING; METAL STENT; MORPHOMETRICS; NONHUMAN; QUANTITATIVE ANALYSIS; SWINE;

EID: 84878322432     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV8I12A218     Document Type: Article

References (43)

1. Onuma Y, Serruys PW. Bioresorbable scaffold: the advent of a new era in percutaneous coronary and peripheral revascularization? Circulation. 2011;123:779-97.
2. Serruys PW, Garcia-Garcia HM, Onuma Y. From metallic cages to transient bioresorbable scaffolds: change in paradigm of coronary revascularization in the upcoming decade? Eur Heart J. 2012;33:16-25.
3. Wykrzykowska JJ, Onuma Y, Serruys PW. Advances in stent drug delivery: the future is in bioabsorbable stents. Expert Opin Drug Deliv. 2009;6:113-26.
4. Heublein B, Rohde R, Kaese V, Niemeyer M, Hartung W, Haverich A. Biocorrosion of magnesium alloys: a new principle in cardiovascular implant technology? Heart. 2003;89:651-6. (Pubitemid 36606211)
5. Waksman R, Pakala R, Kuchulakanti PK, Baffour R, Hellinga D, Seabron R, Tio FO, Wittchow E, Hartwig S, Harder C, Rohde R, Heublein B, Andreae A, Waldmann KH, Haverich A. Safety and efficacy of bioabsorbable magnesium alloy stents in porcine coronary arteries. Catheter Cardiovasc Interv. 2006;68:607-17. (Pubitemid 44546055)
6. Erne P, Schier M, Resink TJ. The road to bioabsorbable stents: reaching clinical reality? Cardiovasc Intervent Radiol. 2006;29:11-6. (Pubitemid 43128134)
7. Erbel R, Di Mario C, Bartunek J, Bonnier J, de Bruyne B, Eberli FR, Erne P, Haude M, Heublein B, Horrigan M, Ilsley C, Bose D, Koolen J, Luscher TF, Weissman N, Waksman R. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet. 2007;369:1869-75. (Pubitemid 46829357)
8. Mani G, Feldman MD, Patel D, Agrawal CM. Coronary stents: a materials perspective. Biomaterials. 2007;28:1689-710. (Pubitemid 46080469)
9. Bosiers M, Deloose K, Verbist J, Peeters P. First clinical application of absorbable metal stents in the treatment of critical limb ischemia: 12-month results. Vascular Disease Management. 2005;2:86-91.
10. Zartner P, Cesnjevar R, Singer H, Weyand M. First successful implantation of a biodegradable metal stent into the left pulmonary artery of a preterm baby. Catheter Cardiovasc Interv. 2005;66:590-4. (Pubitemid 41779033)
11. Böse D, Eggebrecht H, Erbel R. Absorbable metal stent in human coronary arteries: imaging with intravascular ultrasound. Heart. 2006;92:892. (Pubitemid 43974046)
12. Barlis P, Tanigawa J, Di Mario C. Coronary bioabsorbable magnesium stent: 15-month intravascular ultrasound and optical coherence tomography findings. Eur Heart J. 2007;28:2319. (Pubitemid 47537770)
13. Ghimire G, Spiro J, Kharbanda R, Roughton M, Barlis P, Mason M, Ilsley C, Di Mario C, Erbel R, Waksman R, Dalby M. Initial evidence for the return of coronary vasoreactivity following the absorption of bioabsorbable magnesium alloy coronary stents. EuroIntervention. 2009;4:481-4.
14. Bosiers M, Peeters P, D'Archambeau O, Hendriks J, Pilger E, Duber C, Zeller T, Gussmann A, Lohle PN, Minar E, Scheinert D, Hausegger K, Schulte KL, Verbist J, Deloose K, Lammer J. AMS INSIGHT- absorbable metal stent implantation for treatment of below-the-knee critical limb ischemia: 6-month analysis. Cardiovasc Intervent Radiol. 2009;32:424-35.
15. Waksman R, Erbel R, Di Mario C, Bartunek J, de Bruyne B, Eberli FR, Erne P, Haude M, Horrigan M, Ilsley C, Bose D, Bonnier H, Koolen J, Luscher TF, Weissman NJ. Early- and long-term intravascular ultrasound and angiographic findings after bioabsorbable magnesium stent implantation in human coronary arteries. JACC Cardiovasc Interv. 2009;2:312-20.
16. McMahon CJ, Oslizlok P, Walsh KP. Early restenosis following biodegradable stent implantation in an aortopulmonary collateral of a patient with pulmonary atresia and hypoplastic pulmonary arteries. Catheter Cardiovasc Interv. 2007;69:735-8. (Pubitemid 46581268)
17. Maeng M, Jensen LO, Falk E, Andersen HR, Thuesen L. Negative vascular remodelling after implantation of bioabsorbable magnesium alloy stents in porcine coronary arteries: a randomised comparison with bare-metal and sirolimus-eluting stents. Heart. 2009;95:241-6.
18. Jabara R, Chronos N, Conway D, Molema W, Robinson K. Evaluation of a novel slow-release paclitaxel-eluting stent with a bioabsorbable polymeric surface coating. JACC Cardiovasc Interv. 2008;1:81-7. (Pubitemid 351445424)
19. Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U, Russell ME. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation. 2003;107:38-42. (Pubitemid 36070930)
20. Kamath KR, Barry JJ, Miller KM. The Taxus drug-eluting stent: a new paradigm in controlled drug delivery. Adv Drug Deliv Rev. 2006;58:412-36. (Pubitemid 43949060)
21. Silber S. Cypher versus taxus: are there differences? J Interv Cardiol. 2005;18:441-6. (Pubitemid 41726993)
22. Miyajima M, Koshika A, Okada J, Ikeda M. Effect of polymer/basic drug interactions on the two-stage diffusion-controlled release from a poly(L-lactic acid) matrix. J Control Release. 1999;61:295-304. (Pubitemid 29413024)
23. Rodriguez AE, Vigo CF, Delacasa A, Mieres J, Fernandez-Pereira C, Bernardi V, Bettinoti M, Rodriguez-Granillo AM, Rodriguez-Granillo G, Santaera O, Curotto V, Rubilar B, Tronge J, Palacios IF, Antoniucci D. Efficacy and safety of a double-coated paclitaxel-eluting coronary stent: the EUCATAX trial. Catheter Cardiovasc Interv. 2011;77:335-42.
24. Pache J, Kastrati A, Mehilli J, Schuhlen H, Dotzer F, Hausleiter J, Fleckenstein M, Neumann FJ, Sattelberger U, Schmitt C, Muller M, Dirschinger J, Schömig A. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol. 2003;41:1283-8. (Pubitemid 36438988)
25. Tung R, Kaul S, Diamond GA, Shah PK. Narrative review: drug-eluting stents for the management of restenosis: a critical appraisal of the evidence. Ann Intern Med. 2006;144:913-9. (Pubitemid 46768132)
26. Jimenez JM, Davies PF. Hemodynamically driven stent strut design. Ann Biomed Eng. 2009;37:1483-94.
27. Perez G, Rodriguez-Granillo AM, Mieres J, Llaurado C, Rubilar B, Risau G, Fernandez-Pereira C, Rodriguez AE. New coating stent design for patients with high-risk coronary lesions for thrombotic events: early and long-term results of the Camouflage registry. J Invasive Cardiol. 2009;21:378-82.
28. Schwartz RS, Edelman E, Virmani R, Carter A, Granada JF, Kaluza GL, Chronos NA, Robinson KA, Waksman R, Weinberger J, Wilson GJ, Wilensky RL. Drug-eluting stents in preclinical studies: updated consensus recommendations for preclinical evaluation. Circ Cardiovasc Interv. 2008;1:143-53.
29. Carter AJ, Aggarwal M, Kopia GA, Tio F, Tsao PS, Kolata R, Yeung AC, Llanos G, Dooley J, Falotico R. Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. Cardiovasc Res. 2004;63:617-24. (Pubitemid 39078675)
30. Nakazawa G, Finn AV, John MC, Kolodgie FD, Virmani R. The significance of preclinical evaluation of sirolimus-, paclitaxel-, and zotarolimus-eluting stents. Am J Cardiol. 2007;100:36M-44M.
31. Turco MA, Ormiston JA, Popma JJ, Mandinov L, O'Shaughnessy CD, Mann T, McGarry TF, Wu CJ, Chan C, Webster MW, Hall JJ, Mishkel GJ, Cannon LA, Baim DS, Koglin J. Polymer-based, paclitaxel-eluting TAXUS Liberte stent in de novo lesions: the pivotal TAXUS ATLAS trial. J Am Coll Cardiol. 2007;49:1676-83. (Pubitemid 46589927)
32. Ali SA, Doherty PJ, Williams DF. Molecular biointeractions of biomedical polymers with extracellular exudate and inflammatory cells and their effects on the biocompatibility, in vivo. Biomaterials. 1994;15:779-85. (Pubitemid 24251995)
33. Witte F, Fischer J, Nellesen J, Crostack HA, Kaese V, Pisch A, Beckmann F, Windhagen H. In vitro and in vivo corrosion measurements of magnesium alloys. Biomaterials. 2006;27:1013-8. (Pubitemid 41566693)
34. Grogan JA, O'Brien BJ, Leen SB, McHugh PE. A corrosion model for bioabsorbable metallic stents. Acta Biomater. 2011;7:3523-33.
35. Kirkland NT, Lespagnol J, Birbilis N, Staiger MP. A survey of bio-corrosion rates of magnesium alloys. Corrosion Science. 2010;52:287-91.
36. Haude M, Erbel R, Erne P, Verheye S, Degen H, Böse D, Vermeersch P, Wijnbergen I, Weissman N, Prati F, Waksman R, Koolen J. Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial. Lancet. 2013 Jan 14. [Epub ahead of print]
37. Moravej M, Mantovani D. Biodegradable metals for cardiovascular stent application: interests and new opportunities. Int J Mol Sci. 2011;12:4250-70.
38. Onuma Y, Serruys PW, Perkins LE, Okamura T, Gonzalo N, Garcia-Garcia HM, Regar E, Kamberi M, Powers JC, Rapoza R, van Beusekom H, van der Giessen W, Virmani R. Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial. Circulation. 2010;122:2288-300.
39. Serruys PW, Ormiston JA, Onuma Y, Regar E, Gonzalo N, Garcia-Garcia HM, Nieman K, Bruining N, Dorange C, Miquel-Hebert K, Veldhof S, Webster M, Thuesen L, Dudek D. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet. 2009;373:897-910.
40. Wenaweser P, Daemen J, Zwahlen M, van Domburg R, Juni P, Vaina S, Hellige G, Tsuchida K, Morger C, Boersma E, Kukreja N, Meier B, Serruys PW, Windecker S. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J Am Coll Cardiol. 2008;52:1134-40.
41. Jensen LO, Tilsted HH, Thayssen P, Kaltoft A, Maeng M, Lassen JF, Hansen KN, Madsen M, Ravkilde J, Johnsen SP, Sorensen HT, Thuesen L. Paclitaxel and sirolimus eluting stents versus bare metal stents: long-term risk of stent thrombosis and other outcomes. From the Western Denmark Heart Registry. EuroIntervention. 2010;5:898-905.
42. Smits PC, Kedhi E, Royaards KJ, Joesoef KS, Wassing J, Rademaker-Havinga TA, McFadden E. 2-year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice. COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTE stent in all-comers: a randomized open label trial). J Am Coll Cardiol. 2011;58:11-8.
43. Räber L, Magro M, Stefanini GG, Kalesan B, van Domburg RT, Onuma Y, Wenaweser P, Daemen J, Meier B, Juni P, Serruys PW, Windecker S. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. Circulation. 2012;125:1110-21.